Screening and Molecular Diagnosis-based Individualized Precision Management of Monogenic Diabetes

NCT06746610 · tracked via the Priya Life Science China tracker

Sponsor

Tianjin Medical University General Hospital

Phase

Not applicable

Started

2022-08-01

Last updated

2024-12-24

Condition(s) studied

Monogenic Diabetes

Investigational drug(s) / intervention(s)

Genetic Screening for Monogenic Diabetes

Genetic Screening for Monogenic Diabetes: This intervention involves genetic testing for monogenic diabetes (MDM) in recruited participants. The testing includes either a panel test specifically targeting genes associated with monogenic diabetes or whole exome sequencing (WES) to comprehensively identify genetic variants linked to MDM. Precise diagnosis and treatmen： 1. The clinical trial of individualized treatment was carried out for the individuals with diabetes with HNF1A mutation. 2. The research team will closely follow up individuals with GCK mutation diabetes after suspending the current hypoglycemic drugs, and evaluate their clinical glucose metabolism related indicators. 3. Observe the dosage of sulfonylurea drugs used in individuals with different disease course and pancreatic function, and observe the impact of disease course and pancreatic function on the success rate of oral drug replacement.

Study summary

The goal of this observational study is to establish a registry, screening, and individualized management platform for patients with monogenic diabetes mellitus(MDM) using internet-based and mobile application software. The main questions it aims to answer are:

* What are the genetic mutations causing MDM in China (genetic landscape)?
* How effective and safe is the individualized, molecular-diagnosis-based management platform for MDM in improving patient outcomes?

Participants will:

* Register in the MDM platform via mobile app or internet-based software
* Undergo genetic screening for MDM diagnosis
* Participate in follow-up visits for individualized management and monitoring of blood glucose control and outcomes

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Diabetes patients who developed before 25 years old; Or they were diagnosed with diabetes before the age of 35, and two or more immediate relatives were diagnosed with diabetes before the age of 45; 2. Body mass index (BMI) at diagnosis \< 28 kg/m2; 3. Anti glutamic acid decarboxylase antibody (GAD Ab), anti islet cell antibody (ICA Ab), and anti insulin autoantibody (IAA Ab) were all negative; Exclusion Criteria: 1. Secondary diabetes patients with other endocrine diseases, such as hyperthyroidism or hypothyroidism, hyperparathyroidism or hypothyroidism, acromegaly, Cushing's syndrome, autoimmune multiple endocrine diseases, etc.; 2. Systemic use of corticosteroids, immunosuppressants, and other drugs within the past 6 months; 3. Patients with malignant tumors.

Primary outcome measure(s)

Genetic landscape of monogenic diabetes mellitus in China — 24 months

Trial sites (1)

Facility	City	Region	Status
Tianjin Medical University General Hospital	Tianjin	China	Recruiting

More Tianjin Medical University General Hospital trials in China

Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder Active, not recruiting

Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders Active, not recruiting

Esketamine Combined With Remimazolam on Postoperative Sleep Disturbance and Anxiety in Patients Recruiting

The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors Recruiting

Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases Recruiting

Other trials for the same condition

China Monogenic Diabetes Registry Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06746610 on ClinicalTrials.gov ↗ ← All trials in China